People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elixir Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $12.0M | $371.5M | 2009 |
Peter S. DiStefano at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter S. DiStefano on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ansbert Gadicke | 1 | 7 |
| Vaughn M. Kailian | 1 | 3 |
| DION MADSEN | 1 | 2 |
| Kenneth Greenberg | 1 | 2 |
| Paul M. Martha | 1 | 1 |
| Vernon Cassin | 1 | 1 |
| Robert Kriebel | 1 | 1 |
| Karen Roberts | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.